CURRICULUM VITAE

Mark H. Tuszynski, M.D., Ph.D.

Professional Address:

Department of Neurosciences-0626
University of California, San Diego
La Jolla, CA 92093

Telephone: (858) 534-8857
FAX: (858) 534-5220

EDUCATION AND PROFESSIONAL EXPERIENCE:

AWARDS:

SPECIALTY BOARDS:

Board certification in Neurology, 1989

ACADEMIC SOCIETIES:

Society for Neuroscience
American Academy of Neurology
American Neurological Association
American Medical Association
International Brain Research Organization
American Society for Neural Transplantation
American Society for Experimental NeuroTherapeutics

EDITORIAL, SCIENTIFIC ADVISORY and PROFESSIONAL BOARDS:

Editorial Board, Experimental Neurology (1997-present)
Editorial Board, Frontiers in Bioscience (1997-present)
Editorial Board, Neurobiology of Disease (2000-present)
Editorial Board, Neurological Disease and Therapy section, Marcel-Dekker publications (2000–present)
Editorial Board, Neural Rehabilitation and Repair (2001-present)
Editorial Board, Lancet Neurology (2001 – 2005)
Scientific Advisory Board, The Paralysis Project (1997-present)
Scientific Advisory Board, Comitato Promotore Telethon (European Neurological disorder charity) (1997-present)
Scientific Advisory Board, The Christopher Reeve Paralysis Foundation (1999-present)
Scientific Advisory Board, Canadian and American Spinal Research Organizations (2000-present)
Program Committee, American Society for Neural Transplantation (1996-1998; Chair, 1999)
Councilor, American Society for Neural Transplantation & Repair (1999-2004)
Executive Committee Member, Neural Repair and Rehabilitation Section of American Neurological Association (ANA) (2000-present)
Chair, Basic Research Subcommittee, Neural Repair and Rehabilitation Committee of ANA (2000-2004)
Faculty of 1000 Review Board (2005–present)
Medical Advisory Board, George G. Glenner Alzheimer's Family Centers (2002 – present)
Vice-Chair, Clinical Practice Committee, American Society for Neural Transplantation & Repair(2002-2004)
Secretary, American Society for Neural Transplantation & Repair (2003-2004)
Public Information Committee, Society for Neuroscience (2005-present)
Member, Center for Ethics and Technology (2005-present)
Medical Scientific Advisory Board, San Diego Alzheimer’s Association (2007-present)

BIOGRAPHICAL INFORMATION:

Birthdate: February 27, 1959, Halifax, Canada.
Citizenship: U.S.
High School: Advanced placement two years.

PUBLICATIONS:

Original Papers:

1. Tuszynski MH, Petito CP. Thalamic aphasia with pathological confirmation. Neurology, 1988; 38:800-802.

2. Rosenberg MB, Friedmann T, Robertson RC, Tuszynski M, Wolff JA, Breakfield XO, Gage FH. Grafting of genetically modified cells to the damaged brain: Restorative effects of NGF expression. Science, 1988; 242:1575-1578.

3. Tuszynski MH, Petito CK, Levy DE. Risk factors and clinical manifestations of pathologically-verified lacunar infarctions. Stroke 1989; 20:990-999.

4. Tuszynski MH, Buzsaki G, Gage FH. NGF enhances graft-induced functional cholinergic reinnervation of the deafferented hippocampal formation. Neuroscience, 1990; 36:33-44.

5. Tuszynski MH, Armstrong D, Gage FH. Basal forebrain cell death following fimbria-fornix transection. Brain Res, 1990; 508:241-248.

6. Barnett J, Baecker P, Routledge-Ward C, Bursztyn-Pettegrew H, Chow J, Nguyen B, Bach C, Chan H, Tuszynski MH, Yoshida K, Rubalcava R, Gage FH. Human beta nerve growth factor obtained from a baculovirus expression system has potent in vitro and in vivo neurotrophic activity. Exp Neurol, 1990; 110:11-24.

7. Tuszynski MH, U H.-S., Amaral DG, Gage FH. Nerve growth factor infusion in primate brain reduces lesion-induced cholinergic neuronal degeneration. Journal of Neuroscience, 1990; 10:3604-3614.

8. Tuszynski MH, Gage FH. Potential use of neurotrophic agents in the treatment of neurodegenerative disorders. Acta Neurobiologica Exp. 1990; 50.

9. Tuszynski MH, U H.-S., Yoshida K, Gage FH. Recombinant human nerve growth factor infusions prevent cholinergic neuronal degeneration in the adult primate brain. Ann Neurol, 1991; 30:625-636.

10. Hainline B, Tuszynski MH, Posner JB. Ataxia in epidural spinal cord compression. Neurology, 1992; 42:2193-2195.

11. Tuszynski MH, Peterson D, Ray J, Baird A, Nakahara Y, Gage FH. Fibroblasts genetically modified to produce nerve growth factor induce robust neuritic ingrowth after grafting to the spinal cord. Exp Neurol, 1994; 126:1-14.

12. Tuszynski MH, Senut MC, Ray J, Roberts J, U H.-S., Gage FH. Somatic gene transfer to the adult primate CNS: In vitro and In vivo characterization of cells genetically modified to secrete nerve growth factor. Neurobiol Dis, 1994; 1:67-78.

13. Tuszynski, MH and Gage, FH. Transient NGF infusions combined with fetal bridging grafts promote long-term cholinergic neuronal rescue and partial functional recovery in the CNS. Proc Nat Acad Sci, 1995; 92:4621-4625.

14. Tuszynski MH and Gage, FH. Restoring the adult neuronal phenotype: Effects of neurotrophic factors and axonal growth substrates. Molec Neurobiol, 1995; 10:151-167.

15. Senut MC, Tuszynski MH, Suhr S, Raymon H, Gage FH. Autologous grafts of cells genetically modified to express human NT-3: Regional differences in responsiveness to the adult brain and spinal cord. Exp Neurol, 1995; 135:36-55.

16. Tuszynski MH, Roberts J, Senut MC, U H.-S., Gage FH. Gene therapy in the adult primate brain: Intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Therapy, 1996;3:305-314.

17. Tuszynski MH, Gabriel K, Gage FH, Suhr S, Rosetti A, Meyer S. Nerve growth factor delivery by gene transfer induces differential outgrowth of sensory, motor and noradrenergic neruties after adult spinal cord injury. Exp Neurol, 1996;137:157-173.

18. Nakahara Y, Senut M-C, Gage FH, Tuszynski MH. Grafts of fibroblasts genetically modified to secrete NGF, BDNF, NT-3 or basic FGF elicit differential responses in the adult spinal cord. Cell Transpl, 1996;5:191-204.

19. Tuszynski MH, Mafong E, Meyer S. Central infusions of brain-derived neurotrophic factor and neurotrophin-4/5, but not nerve growth factor and neurotrophin-3, prevent loss of the cholinergic phenotype in injured adult motor neurons. Neuroscience, 1996;71:761-771.

20. Thal LJ, Carta A, Clarke WR, Ferris SH, Friedland RP, Petersen RB, Pettegrew JW, Pfeiffer E, Raskind MA, Sano M, Tuszynski MH, Woolson RF. A one-year multicenter placebo-controlled trial of Acetyl-L-carnitine in patients with Alzheimer's disease. Neurology, 1996;47:705-711.

21. Winkler J, Ramirez GA, Kuhn H, Peterson DA, Tuszynski MH, Gage FH, Thal LJ. Reversible induction of Schwann cell hyperplasia and sprouting of sensory and sympathetic neurites in vivo after continuous intracerebroventricular administration of nerve growth factor. Ann Neurol, 1996;40:128-139.

22. Tuszynski MH, Murai K, Blesch A, Grill R, Miller I. Functional characterization of NGF-secreting cell grafts to the acutely injured spinal cord. Cell Transpl, 1997;6:361-368.

23. Eberling JL, Roberts JA, Rapp PR, Tuszynski MH, Jagust WJ. Glucose cerebral metabolism and memory in aged rhesus macaques. Neurobiol Aging, 1997;18:437-443.

24. Tuszynski MH. Neuronal loss and Alzheimer's disease: Potential effects of neurotrophic factors. Whitehouse, P., ed. Proceedings of the ANA Conference on Alzheimer's Disease, University of Virginia Press, 1997.

25. Grill R, Blesch A, Tuszynski MH. Robust growth of chronically injured spinal cord axons induced by grafts of genetically modified NGF-secreting cells. Exp Neurol, 1997;148:444-452.

26. Grill R, Murai K, Blesch A, Gage FH, Tuszynski MH. Cellular delivery of neurotrophin-3 promotes corticospinal axonal growth and partial functional recovery after spinal cord injury. Journal of Neuroscience, 1997;17:5560-5572.

27. Tuszynski M, Weidner N, McCormack M, Miller I, Powell H, Conner J. Grafts of genetically modified Schwann cells to the spinal cord: Survival, axon growth and myelination. Cell Transpl, 1998;7:187-196.

28. Tuszynski MH, Smith DE, Roberts J, McKay H, Mufson E. Targeted intraparenchymal delivery of human NGF by gene transfer to the primate basal forebrain for 3 months does not accelerate ß-amyloid plaque deposition. Exp Neurol, 1998;154:573-582.

29. Blurton-Jones MM, Roberts J, Tuszynski MH. Estrogen receptor immunoreactivity in the adult primate brain: neuronal distribution and association with p75, trk A, and choline acetyltransferase. J Comp Neurol, 1999;405:529-542.

30. Blesch A, Uy HS, Grill RJ, Cheng JG, Patterson PH, Tuszynski MH. LIF augments neurotrophin expression and corticospinal axon growth after adult CNS injury. Journal of Neuroscience, 1999;19: 3556-3566.

31. Tuszynski MH, Gabriel K, Gerhardt K, Szollar S. The human spinal cord retains substantial structural mass in chronic stages after injury. J Neurotrauma, 1999;16:523-531.

32. Weidner N, Blesch A, Grill R, Tuszynski MH. NGF-hyerpsecreting Schwann cell grafts augment and guide spinal cord axonal growth, and remyelinate CNS axons in a phenotypically appropriate manner that correlates with expression of L1. J Comp Neurol, 1999;413:495-506.

33. Weidner N, Grill RJ, Tuszynski MH. Elimination of basal lamina and the collagen “scar” after spinal cord injury fails to augment corticospinal tract regeneration. Exp Neurol, 1999;160:40-50.

34. Smith DE, Roberts J, Gage FH, Tuszynski MH. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc Nat Acad Sci, 1999;96:10893-10898.

35. Blesch A, Uy HS, Diergardt N, Tuszynski MH. Neurite outgrowth can be modulated in vitro using a tetracycline-repressible gene therapy vector expressing human nerve growth factor.
J Neurosci Res, 2000;59:402-409.

36. Merrill DA, Roberts JA, Tuszynski MH. Conservation of neuron number and size in entorhinal cortex layers II, III and V/VI of aged primates. J Comp Neurol, 2000;422:396-401.

37. Bowes M, Tuszynski MH, Conner J, Zivin JA. Continuous intrathecal fluid infusions elevate NGF levels and prevent functional deficits after spinal cord ischemia. Brain Res, 2000: 883:178-183.

38. Tuszynski MH. Intraparenchymal NGF infusions rescue degenerating cholinergic neurons. Cell Transpl, 2000; 9:629-636.

39. Blurton-Jones MM, Tuszynski MH. Reactive astrocytes express estrogen receptors
in the injured primate brain. J Comp Neurol, 2001; 433:115-123.

40. Lu P, Blesch A, Tuszynski MH. Neurotrophism without neurotropism: BDNF promotes survival but not growth of lesioned corticospinal neurons. J Comp Neurol, 2001;436:456-470.

41. Conner JM, Darracq MA, Roberts J, Tuszynski MH. Non-tropic actions of neurotrophins: Subcortical NGF gene delivery reverses age-related degeneration of primate cortical cholinergic innervation. Proc Nat Acad Sci, 2001; 98:1941-1946.

42. Weidner N, Ner A, Salimi N, Tuszynski MH. Spontaneous corticospinal axonal plasticity and functional recovery after adult CNS injury. Proc Nat Acad Sci, 2001; 98:3513-3518.

43. Blesch A, Tuszynski MH. GDNF gene delivery to injured adult CNS motor neurons promotes axonal growth, expression of the trophic neuropeptide CGRP and cellular protection.
J Comp Neurol, 2001;436:399-410.

44. Blesch A, Conner JM, Tuszynski MH. Modulation of neuronal survival and axonal growth in vivo by tetracycline-regulated neurotrophin expression. Gene Therapy, 2001;8:954-960.

45. Jones LL, Tuszynski MH. Chronic intrathecal infusions after spinal cord injury cause scarring and compression. Microscopy Res Tech, 2001;54:317-324.

46. Merrill DA, Chiba AA, Tuszynski MH. Conservation of neuronal number and size in the entorhinal cortex of behaviorally characterized aged rats. J Comp Neurol, 2001; 438:445-456.

47. Jones LL, Yamaguchi Y, Stallcup WB, Tuszynski MH. NG2 is a major chondroitin sulfate proteoglycan produced after spinal cord injury and is secreted by macrophages and oligodendrocyte progenitors. Journal of Neuroscience, 2002, 22:2792-2803.

48. Tuszynski MH, Grill R, Jones LL, McKay HM, Blesch A. Spontaneous and augmented growth of axons in the primate spinal cord: Effects of local injury and NGF-secreting cell grafts. J Comp Neurol, 2002; 449:88-101.

49. Jones LL, Tuszynski MH. Spinal cord injury elicits expression of keratan sulfate proteoglycans by oligodendrocyte progenitors, reactive microglia and macrophages. Journal of Neuroscience, 2002, 22:4611-4624.

50. Blurton-Jones M, Tuszynski MH. Estrogen receptor-beta co-localizes extensively with parvalbumin-labeled inhibitory neurons in the cortex, amygdala, basal forebrain, and hippocampal formation of intact and ovariectomized adult rats. J Comp Neurol, 2002; 438:445-456.

51. Lacroix S, Chang L, Rose-John S, Tuszynski MH. Delivery of hyper-interleukin-6 to the injured spinal cord increases neutrophil and macrophage infiltration and inhibits axonal growth. J Comp Neurol, 2002;454:213-228.

52. Lu P, Jones LL, Snyder EY, Tuszynski MH. Neural stem cells constitutively secrete neurotrophic factors and promote robust host axonal growth after spinal cord injury. Exp Neurol, 2003;181:115-129.

53. Merrill DA, Karim R, Darraq M, Chiba AA, Tuszynski MH. Hippocampal neurogenesis does not correlate with spatial learning in aged rats. J Comp Neurol, 2003; 459:201-207.

54. Tuszynski MH, Grill RJ, Jones LL, Brant A, Blesch A, Löw K, Lacroix S, Lu P. NT-3 gene delivery elicits growth of chronically injured corticospinal axons and modestly improves functional deficits after chronic scar resection. Exp Neurol, 2003; 181:47-56.

55. Jones LL, Margolis RU, Tuszynski MH. The chondroitin sulfate proteoglycans neurocan, brevican, phosphocan and versican are differentially regulated following spinal cord injury. Exp Neurol, 2003;189:392-411.

56. Conner JM, Culberson A, Packowski C, Chiba A, Tuszynski MH. Lesions of the basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity associated with motor skill learning. Neuron, 2003, 38:819-829.

57. Blesch A, Tuszynski MH. Cellular GDNF gene delivery promotes growth of motor and dorsal column sensory axons after partial and complete spinal cord transactions and induces remyelination . J Comp Neurol, 2003; 4467:403-417.

58. Tobias CA, Shumsky JS, Shibata M, Tuszynski MH, Fischer I, Tessler A, Murray M. Delayed grafting of BDNF and NT-3 producing fibroblasts into the injured spinal cord stimulates sprouting, partially rescues axotomized red nucleus neurons from loss and atrophy and provides limited regeneration. Exp Neurol, 2003;184:97-113.

59. Blurton-Jones M, Kuan PN, Tuszynski MH. Anatomical evidence for trans-synaptic influences of estrogen on BDNF expression. J Comp Neurol, 2003;468:346-360.

60. Jones LL, Sajed D, Tuszynski MH. Axonal regeneration through regions of CSPG deposition after spinal cord injury: A balance of permissiveness and inhibition. Journal of Neuroscience, 2003;23:9276-9288.

61. Lacroix S, Havton L, McKay H, Yang H, Brant A, Roberts J, Tuszynski MH. Bilateral corticospinal projections from unilateral motor areas in macaque monkeys: a quantitative study. J Comp Neurol, 2004;473:147-161.

62. Stokols S, Tuszynski MH. The fabrication and characterization of linearly oriented nerve guidance scaffolds for spinal cord injury. Biomaterials, 2004;25:5839-5846.

63. Smith DE, Rapp PR, McKay HM, Roberts JA, Tuszynski MH. Memory impairment in aged primates is associated with focal death of cortical neurons and atrophy of subcortical neurons. Journal of Neuroscience, 2004;24:4373-4381.

64. Lu P, Yang H, Jones LL, Filbin MT, Tuszynski MH. Combinatorial therapy with neurotrophins and cAMP promotes axonal regeneration beyond sites of spinal cord injury. Journal of Neuroscience, 2004; 24:6402-6409.

65.Lu P, Blesch A, Tuszynski MH. Induction of bone marrow stromal cells to neurons: differentiation, transdifferentiation, or artifact? J Neurosci Res, 2004; 77:174-191.

66. Steeves J, Fawcett J, Tuszynski MH. Report of international clinical trials workshop on spinal cord injury. Spinal Cord, 2004;42:591-597

67. Lu P, Jones LL, Tuszynski MH. BDNF-expressing marrow stromal cells support extensive axonal growth at sites of spinal cord injury. Exp Neurol, 2005 191:344-60.

68. Blesch A, Pfeiffer A, Conner JM, Britton W, Verma I, Tuszynski MH. Regulated lentiviral NGF genetransfer controls rescue of medial septal cholinergic neurons. Molec Ther, 2005;11:916-925.

69. Conner JM, Chiba AA, Tuszynski MH. The basal forebrain cholinergic system is essential for cortical plasticity and functional recovery following brain injury. Neuron, 2005, 46:173-9.

70. Courtine G, Roy RR. Hodgson J, McKay HM, Zhong H, Yang H, Tuszynski MH,
Edgerton VR. Kinematic and EMG determinants in quadrupedal locomotion of a non-human primate. J Neurophysiol, 2005, 93:3127-3145.

71. Spinal Cord Translational Study Group (Tuszynski MH, corresponding author). Recommended guidelines for studies of human subjects with spinal cord injury. Spinal Cord, 2005, 43:453-458.

72. Tuszynski MH, Thal L, Pay M, Salmon DP, U H-S, Bakay R, Patel P, Blesch A, Vahlsing HL, Ho G, Tong G, Potkin SG, Fallon J, Hansen L, Mufson EJ, Kordower JH, Gall C, Conner JM. A phase I clinical trial of nerve growth factor gene therapy for Alzheimer’s disease. Nature Medicine, 2005, 11:551-555.

73. Courtine G, Roy RR, Hodgson J, McKay H, Yang H, Zhong H, Tuszynski MH, Edgerton R. Performance of locomotion and foot grasping following a unilateral thoracic corticospinal tract lesion in monkeys (Macaca Mulatta). Brain, 2005;128:2338-2358.

74. Stokols S, Tuszynski MH. Freeze-dried agarose scaffolds with uniaxial channels stimulate and guide linear axonal regeneration following spinal cord injury. Biomaterials, 2006;27:443-51

75. Yang H, Lu P, McKay HM, Bernot T, Keirstead H, Steward O, Gage FH, Edgerton ER, Tuszynski MH. Endogenous neurogenesis replaces oligodendrocytes and astrocytes after primate spinal cord injury. J Neurosci, 2006;26:2157-2166

76. Stokols S, Sakamoto J, Breckon C, Holt T, Weiss J, Tuszynski MH. Templated agarose scaffolds support linear axonal regeneration. Tissue Engineering, 2006; 12:2777-2787. 

77. Blurton-Jones M, Tuszynski MH. Estradiol-induced modulation of estrogen receptor-ß and GABA within the adult neocortex: A potential trans-synaptic mechanism for estrogen modulation of BDNF. J Comp Neurol, 2006, 499:603-12.

78. Ramanathan D, Conner JM, Tuszynski MH. A form of motor cortical plasticity that correlates with recovery of function after brain injury. Proc Natl Acad Sci, 2006;103 30:11370-11375.

79. Taylor L, Jones LL, Tuszynski MH, Blesch A. NT-3 gradients established by lentiviral gene delivery promote short-distance axonal bridging beyond cellular grafts in the injured spinal cord. Journal of Neuroscience, 2006; 26:9713-9721.

80. Tuszynski MH. Challenges to the report of nogo antibody effects in primates. Nature Medicine 2006, 12:1231-1232 (letter)

81. Lu P, Yang H, Culbertson M, Graham L, Roskams AJ, Tuszynski MH. Olfactory ensheathing cells do not exhibit unique migratory or axonal growth-promoting properties after spinal cord injury. Journal of Neuroscience, 2006: 26:11120-11130.

82. Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord, 2007; 45:190-205.

83. Steeves JD, Lammertse D, Curt A, Fawcett JW, Tuszynski MH, et al. Guidelines for the conduct of clinical trials for spinal cord injury (SCI) as developed by the ICCP panel: clinical trial outcome measures. Spinal Cord, 2007; 45:206-221.

84. Tuszynski MH, Steeves JD, Fawcett JW, Lammertse D, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP Panel: clinical trial inclusion/exclusion criteria and ethics. Spinal Cord, 2007; 45:222-231.

85. Lammertse D, Tuszynski MH, Steeves JD, Curt A, Fawcett JW, et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: clinical trial design. Spinal Cord, 2007; 45:232-242.

86. Lu P, Jones LL, Tuszynski MH. Axon regeneration through scars and into sites of chronic spinal cord injury. Exp Neurol, 2007; 203:8-21.

87. Herzog CD, Dass B, Holden JE, Stansell J, Gasmi M, Tuszynski MH, Bartus RT, Kordower JH. Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Movement Disorders 2007; 22:1124-1132.

88. Tuszynski MH. Rebuilding the brain: resurgence of fetal grafting. Nature Neuroscience, News and Views. 2007, in press.

89. Hollis ER, Kadoya K, Samulski RJ, Tuszynski MH. Retrograde infection following peripheral injection of self-complementary AAV serotypes. Molecular Therapeutics, in press.

90. Blesch A, Tuszynski MH. Transient growth factor delivery sustains regenerated axons after spinal cord injury. Journal of Neuroscience, 2007, in press.

Selected Chapters and Reviews:

1. Tuszynski MH, Gage FH. Neural grafting in neurodegenerative diseases. ISI Atlas of Science, 1988; 2:229-234.

2. Tuszynski MH, Jinnah HA, Gage FH. Delivery of neuroactive compounds to the brain: Potential utility of genetically-modified cells. Neurobiol Aging, 1989; 10: 644-645.

3. Chen KC, Tuszynski MH, Gage FH. Role of neurotrophic factors in Alzheimer's disease. Neurobiol Aging, 1989; 10:545-546.

4. Gage FH, Tuszynski MH, Chen K, Armstrong D, Buzsaki G. Survival, growth and function of damaged cholinergic neurons. Central Cholinergic Synaptic Transmission. Experientia supplementa, 1989; 57:259-274.

5. Gage FH, Fisher LJ, Jinnah H, Rosenberg MB, Tuszynski MH, Rae J, Friedmann T. Grafting genetically modified cells to the brain: Conceptual and technical issues. Prog Brain Res, 1990; 82:1-10.

6. Tuszynski MH, Chen K, Gage FH. Neurotrophic factors in the CNS: Possible therapeutic interventions. In: Proceedings of the Third National Conference on Alzheimer's Disease and Dementia. Altman HJ, ed. Plenum Press, New York. 1990.

7. Gage FH, Chen KS, Tuszynski MH, Fagan A. Functions of NGF on central cholinergic neurons. In: Brain Repair. Aguayo AJ, Ottoson D, ed. Macmillan Press, London. 1990.

8. Gage FH, Rosenberg MB, Tuszynski MH, Yoshida K, Armstrong DM, Hayes R, Friedmann T. Gene therapy in the CNS: Intracerebral grafting of genetically modified cells. Prog Brain Res, 1990; 86:205-217.

9. Gage FH, Tuszynski MH, Chen K, Higgins G. NGF function in the central nervous system. In: Current Topics in Microbiology and Immunology, Bothwell M, ed. Springer-Verlag, Berlin. p71-94, 1991.

10. Gage FH, Tuszynski MH, Yoshida K, Higgins G. Nerve growth factor expression and function in the CNS. In: Growth Factors and Alzheimer's Disease, Hefti F, Brachet P, Will B, Christen Y, eds. Springer-Verlag, Berlin. p106-116. 1991.

11. Tuszynski MH, Gage FH. In vivo assay of neuron-specific effects of nerve growth factor. In: Meth Enzymol, 1991; 198:35-47.

12. Gage FH, Tuszynski MH, Chen KS, Fagan AM, Higgins GA. Nerve growth factor function in the central nervous system. Curr Top Microbiol Immunol, 1991; 165:71-93.

13. Chen KS, Tuszynski MH, Higgins GA, Gage FH. Functional effects of chronic nerve growth factor infusions on adult and aged basal forebrain cholinergic neurons. In: Khachiturian ZS and Blass JP, ed. Alzheimer's Disease. New Treatment Strategies. Marcel Dekker, Inc. New York. p103-124. 1992.

14. Tuszynski MH, Gage FH. Neurotrophic factors and neuronal loss: Potential relevance to Alzheimer's disease. In: Alzheimer's Disease. Terry R, Katzman R, Bick KL, eds. Raven Press, New York. 1994. pp.405-418.

15. Tuszynski MH, Gage FH. Neurotrophic factors and diseases of the nervous system. Ann Neurol, 1994; 35:S9-12.

16. Gage FH, Chalmers GR, Eagle KL, Kawaja MD, Tuszynski MH. Functional recovery following damage to the adult septohippocampal system. In: Neurobehavioral Plasticity: Learning, Development and Response to Brain Insults. Spear NE, Sprear LP, Woodruff M (eds). Lawrence Erlbaum Assoc. Publishers, Trenton 1994.

17. Gage FH, Buzsaki G, Tuszynski MH. Reconstruction of the basal forebrain cholinergic circuits of the aged and young brain-damaged rat. Current Communications in Molecular Biology: The Molecular Biology of Alzheimer's Disease. 1995.

18. Tuszynski MH, Gage FH. Neuronal Growth and Transplantation in the Adult Central Nervous System. In: Princples of Medical Biology. Bittar E, Bittar R, ed. JAI press, Inc. New York. 1999.

19. Gage FH, Eagle K, Tuszynski MH. NGF dependent regeneration of adult septal cholinergic axons into denervated hippocampus. In: Life and Death in the Nervous System. Ibanez C, Fuxe K, Hokfelt T, Jornvall H, Olson L, Ottoson D, ed. Proceedings of the Wenner-Gren International Series, 1995.

20. Tuszynski MH, Gage FH. Somatic gene therapy for nervous system disease. CIBA Foundation Symposia, 1996;196:85-97.

21. Tuszynski MH. The future of neuronal growth factors for neurological disease. Western Journal of Medicine, in press.

22. Blesch A, Tuszynski MH. Gene therapy for neurological disorders. Clinical Neuroscience, 1996;3:268-274.

23. Tuszynski MH. Gene therapy for neurodegenerative disease. Ann NY Acad Sci, 1997;835:1-11.

24.  b. Gene therapy: A new strategy for the treatment of neurological disease. The Neuroscientist, 1998; 4:398-407.

25. Conner J, Tuszynski MH. Growth factor therapy. Mental Retardation and Develop. Disabilities Res Rvw, 1998;4:212-222.

26. Blesch A, Grill RJ, Tuszynski MH. Neurotrophin gene therapy in CNS models of trauma and degeneration. In: Progress in Brain Research. Neuronal Degeneration and Regeneration: From Basic Mechanisms to Prospects for Therapy. Van Leeuwen FW, Salehi A, Giger RJ, Holtmaat AJGD, and Verhaagen J, eds. Elsevier, Amsterdam. 1998.

27. Grill R, Tuszynski MH. Axonal responses to injury. In: CNS Regeneration: Basic Science and Clinical Applications, Tuszynski MH and Kordower JH, eds. Academic Press, San Diego. 1999. pp 27-54.

28. Tuszynski MH. Neurotrophic factors. In: CNS Regeneration: Basic Science and Clinical Applications, Tuszynski MH and Kordower JH, eds. Academic Press, San Diego. 1999. pp 109-158.

29. Kordower JH, Tuzynski MH. Fetal neuronal grafting for CNS regeneration. In: CNS Regeneration: Basic Science and Clinical Applications, Tuszynski MH and Kordower JH, eds. Academic Press, San Diego. 1999. pp 159-182.

30. Tuszynski MH, Gage FH, Mufson EJ, Kordower JH. Neurotrophic factors, gene therapy and Alzheimer's disease. In: CNS Regeneration: Basic Science and Clinical Applications, Tuszynski MH and Kordower JH, eds. Academic Press, San Diego. 1999. pp 505-528.

31. Tuszynski MH, Grill R, Blesch A. Spinal cord regeneration. In: CNS Regeneration: Basic Science and Clinical Applications, Tuszynski MH and Kordower JH, eds. Academic Press, San Diego. 1999. pp 605-630.

32. Grundman M, Tuszynski MH. Designing clinical trials for neural repair. In: CNS Regeneration: Basic Science and Clinical Applications, Tuszynski MH and Kordower JH, eds. Academic Press, San Diego. 1999. pp 647-662.

33. Conner JM, Tuszynski MH. The relationship of lesion-induced damage to central cholinergic systems to Alzheimer's disease: lessons from NGF studies. In: Innovative Animal Models of Central Nervous System Diseases: From Molecule to Therapy edited by D.F. Emerich, R.L. Dean III and P.R. Sandberg, Totowa: Humana Press, 2002.

34. Blesch A, Tuszynski MH. Ex vivo gene therapy in the CNS. Handbook Exper Pharm, 2002: Springer, Berlin.

35. Lacroix S, Tuszynski MH. Responses of injured spinal cord axons to grafts of cells genetically modified to produce trophic factors. In: Neurorehabilitation and Neural Repair, Selzer ME, ed. 2000;14:265-75.

36. Lu P, Tuszynski MH. Stem cells for spinal cord injury. In: Neural Stem Cells for Brain and Spinal Cord Repair. 2002. Zigova T, Snyder EY and Sanberg PR, eds. Humana Press, Totowa, NJ.

37. Blesch A, Tuszynski MH. Neurotrophic factors and gene therapy in spinal cord injury. Topics in Spinal Cord Injury Rehab, 2000; 6:42-51.

38. Tuszynski MH. Ex vivo NGF gene therapy for Alzheimer’s disease. In: Proceedings of the First Annual Institute for the Study of Aging Alzheimer’s Symposium. Spring-Verlaag, 2000.

39. Blesch A, Lu P, Tuszynski MH. Neurotrophic factors, gene therapy and neural stem cells for spinal cord repair. Brain Res Bull, 2002; 57:833-838.

40. Weidner N, Tuszynski MH. News & Views: Spontaneous plasticity in the injured spinal cord – implications for repair strategies. Molecular Psychiatry, 2002;7:9-11.

41. Blesch A, Tuszynski MH. Spontaneous and neurotrophin-induced axonal plasticity after spinal cord injury. Prog Brain Res, 2002;137:413-421.

42. Jones LL, Oudega M, Bunge MB, Tuszynski MH. Neurotrophic factors, cellular bridges and gene therapy for spinal cord injury. J Physiol, 2001;533:83-89.

43. Merrill DA, Blesch A, Tuszynski MH. Therapeutic potential of nervous system growth factors for neurodegenerative disease. Exp Therapeutics, 2002; 2:89-96.

44. Tuszynski MH, Conner JM, Blesch A, Smith D, Merrill DA, Vahlsing HL. New strategies in neural repair. Prog Brain Res, 2002; 138:401-420.

45. Tuszynski MH. Gene therapy for neurodegenerative disorders. The Lancet Neurology, 2002; 1:51-57.

46. Blesch A, Tuszynski MH (2002). Ex vivo gene therapy in the CNS. In: Marcoux FW, Choi DW (eds.) CNS Neuroprotection (Handbook of Experimental Pharmacology Vol. 155). pp. 301-324

47. Tuszynski MH, Thal L, U HS, Pay MM, Blesch A, Conner J, Vahlsing HL. Nerve growth factor gene therapy for Alzheimer's disease. J Mol Neurosci. 2002;19:207.

48. Tuszynski MH, U HS, Alksne J, Bakay RA, Pay MM, Merrill DA, Thal LJ. Growth factor gene therapy for Alzheimer’s disease. Neurosurgical Focus, 2002l 13:e5.

49. Tuszynski MH. Gene therapy for neurological disease. Expert Opin. Biological Therapy. 2003;3:815-828.

50. Tuszynski MH. Neurotrophic factors for Alzheimer’s disease. In: Current Clinical Neurology, Alzheimer’s Disease: A Physician’s Guide to Practical Management, Richter RW and Richeter BZ, ed. 2003, Humana Press Inc., Totowa, N.J.

51. Tuszynski MH, Blesch A. Nerve growth factor: From animal models of cholinergic neuronal degeneration to gene therapy in Alzheimer’s disease. In: Progress in Brain Research. Aloe E, ed. Elsevier, 2003; 146:441-449.

52. Tuszynski MH. Prospects for Gene Therapy for CNS Disease. In: Neuroscience, Molecular Medicine and the Therapeutic Transformation of Neurology. Waxman S, ed. Elsevier Press, San Diego, 2004.

53. Blesch A, Tuszynski MH. Nucleus hears axon’s pain. Nature Med, 2004;10:236-237.

54. Nagahara A, Tuszynski MH. The ageless question: what accounts for age-related cognitive decline? Science SAGE KE, 2004:pe20

55. Imitola J, Park KI, Teng YD, Nisim S, Lachyankar M, Ourednik J, Mueller FJ, Yiou R, Atala
A, Sidman RL, Tuszynski M, Khoury SJ, Snyder EY. Stem cells: cross-talk and
developmental programs. Philos Trans R Soc Lond B Biol Sci 2004;359:823-837.

56. Lu P, Tuszynski MH. Can bone marrow-derived stem cells differentiate into functional neurons? Exp Neurol, 2005;193:273-278.

57. Tuszynski MH. New strategies for CNS repair. LE-TeX. In: Schering Foundation
Workshop 53 - Opportunities and Challenges of the Therapies Targeting CNS Regeneration.
Springer-Verlag, 2005; 53:1-10.

58. Blight A, Tuszynski MH. Clinical trials in spinal cord injury. J Neurotrauma. 2006; 23:586-593.

59. Conner JM, Tuszynski MH. Neurotrophins: physiology and pharmacology. Encyclopedia of Neuroscience. Elsevier, San Diego. 2007.

60. Blesch A, Tuszynski MH. Neurotrophic factor therapy: NGF, BDNF and NT-3. Encyclopedia of Neuroscience. Elsevier, San Diego. 2007.

61. von dem Bussche M, Tuszynski MH. Growth Factor and Neuron Atrophy. Encyclopedia of Neuroscience. Elsevier, San Diego. 2007.

62. Nagahara A, Tuszynski MH. Growth factors in Alzheimer’s disease. In: Alzheimer’s Disease, eds. Sisodia A and Tanzy R. Elsevier, San Diego. 2007.

63. Tuszynski MH. Nerve growth factor gene delivery: Animal models to clinical trials. Dev Neurobiol 2007; in press.

64. Tuszynski MH. Nerve growth factor gene therapy in Alzheimer’s disease. Alzheimer’s Disease and Associated Disorders. 2007; 21:179-189.

65. Blesch A, Tuszynski MH. Neurotrophic factors in Alzheimer’s disease. In: CNS Regeneration, Ed. 2. Kordower J and Tuszynski MH, editors. Elsevier, San Diego. 2007.

66. Tuszynski MH, Lu P. Axonal plasticity and regeneration in the injured spinal cord. In: CNS Regeneration, Ed. 2. Kordower J and Tuszynski MH, editors. Elsevier, San Diego. 2007.

67. Johnson E, Tuszynski MH. Neurotrophic factors. In: CNS Regeneration, Ed. 2. Kordower J and Tuszynski MH, editors. Elsevier, San Diego. 2007.

68. Lu P, Tuszynski MH. Growth factors and combinatorial therapies for CNS regeneration. Exp Neurol, 2007; in press.

BOOKS:

Tuszynski MH, Kordower JA, eds. CNS Regeneration: Basic Science and Clinical Aspects. Academic Press, San Diego. 1999.

Kordower JA, Tuszynski MH, eds. CNS Regeneration: Basic Science and Clinical Aspects. 2nd Edition. Elsevier, San Diego. 2007.

EDITOR FOR SPECIAL JOURNAL ISSUES:

Tuszynski MH, Bakay R, eds. Cell Transplantation special issue: Proceedings of the 4th Annual American Society for Neural Transplantation. 1999.

Tuszynski MH, ed. Topics in Spinal Cord Injury Rehabilitation. 2000; 6:2.

OTHER:

Reviewer for Science, Nature, Nature Neuroscience, Nature Medicine, Nature Reviews, Proceedings of the National Academy of Sciences, Journal of Neuroscience, Journal of Comparative Neurology, and others.

Grant reviewer for NIH (including Chair, FORE-SCI Study section), Medical Research Council of the UK, Veterans Administration, The Wellcome Trust, The Alzheimer’s Association, Christopher Reeve Paralysis Association, Paralyzed Veterans of America, Paralysis Project, National Paralysis Association, Heumann Foundation and others.